The Accel Pharma group is a leading pharmaceutical research and development firm specialized on creating breakthrough therapies for rare diseases with sparse existing treatment options. Founded in 2010, the company has rapidly grown its footprint across 30 countries, with headquarters in Boston, London, and Singapore. Its core mission is to accelerate the delivery of life-changing treatments to patients who have not had access to effective care for their conditions.
The company’s research and development pipeline includes more than 35 active drug candidates, spanning early-stage discovery to phase 3 clinical testing across four key therapeutic areas: cancer care, immune system disorders, brain and nervous system therapeutics, and orphan drug development. Its flagship drug candidate targeting a rare childhood cancer has shown promising results in phase 2 trials, with patient response data exceeding industry benchmarks by 28%, marking a promising advance in treating a condition with no previously approved therapies.
Accel Pharma leverages state-of-the-art technologies including machine learning-enabled compound screening to reduce development timelines by up to 30% and boost trial success metrics for new drug candidates. Accel Pharma also partners with leading academic institutions and global health organizations to increase patient access to new drugs in underserved global regions. These cross-sector alliances have enabled Accel Pharma to fast-track the development of affordable generics for prevalent non-communicable diseases that are cost-prohibitive for large patient populations in emerging markets.
To date, Accel Pharma has been granted regulatory approval for 10 of its drug candidates in leading healthcare markets including the US, EU, and Japan. The company's focus on fair healthcare access has led to cost-support initiatives that make treatments accessible to low-income patients regardless of their income level or insurance status. In the past 12 months, Accel Pharma launched a international patient support scheme to distribute affordable its approved immunotherapy drugs to underserved communities across the Global South, with plans to expand the program to 22 new regions by 2026.
Alongside its primary pharmaceutical activities, Accel Pharma has implemented strict environmental sustainability policies to minimize its environmental impact by 35% by 2030, with targets to achieve net-zero operational emissions by 2040. The organization also adheres to strict ethical guidelines for all its clinical trials, with transparent participant consent frameworks and unbiased regulatory monitoring to safeguard trial participants at every stage of the research process.
Looking ahead, Accel Pharma plans to expand its pipeline to include treatments for Alzheimer's disease and gene therapies for rare genetic disorders, with 10 new candidates entering early-stage clinical trials by the end of 2025. Its long-term goal is to eliminate unmet medical needs for over 1 billion people living with underserved medical conditions by 2035, while maintaining its dedication to patient-centric pricing for all approved therapies.